Compare Mast Therapeutics vs Merrimack Pharmaceuticals
Customers evaluate the quality of Mast Therapeutics's products using the following success metrics.
Overview
Mast Therapeutics is 29 yrs old and is based in United States.
Mast Therapeutics (NYSEMKT: MSTX), fka ADVENTRX Pharmaceuticals, is a biopharmaceutical company focused on in-licensing, developing, and commercializing proprietary product candidates primarily for the treatment of cancer. Mast's lead product candidate, AIR001, is a sodium nitrite solution for intermittent inhalation via nebulization in Phase 2 clinical development for the treatment of HFpEF.
Merrimack Pharmaceuticals is 31 yrs old and is based in United States.
Merrimack Pharmaceuticals (NASDAQ: MACK) is a biopharmaceutical company discovering, developing, and commercializing medicines paired with companion diagnostics for the treatment of serious diseases, with a focus on cancer. The company's mission is to provide patients, physicians, and the healthcare system with the medicines, tools, and information to transform the approach to care from one based on the identification and treatment of symptoms to one focused on the diagnosis and treatment of illness through a more precise mechanistic understanding of disease.
Demo Video
Leadership
Carrie McQueen (Chief Financial Officer)
Robert J Mulroy (Chief Executive Officer, President)
Funding
Investors
Savara, Centrum Bank AG
Sorenson Development, GTC Biotherapeutics
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Mast Therapeutics has not claimed their profile.
Work for Mast Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Mast Therapeutics?
Claim your profile now.
Information not available because Merrimack Pharmaceuticals has not claimed their profile.
Work for Merrimack Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Merrimack Pharmaceuticals?
Claim your profile now.